Tag Archives: cloud

Survey of the general population in France identifies knowledge gaps in the perception of lung cancer

Lung cancer management in recent years has improved patient outcomes because of screening, improved surgery and radiotherapy in early and locally-advanced stages of disease, new chemotherapies, validated maintenance therapy, and effective targeted therapies. However, fears or misperceptions about lung cancer may alter physician-patient communications and could delay lung cancer screening, diagnosis, or treatment…

Male, female breast cancers are not identical — ScienceDaily

Dr. Fatima Cardoso of the Champalimaud Clinical Center in Lisbon and coordinator of this study says, “This study aims to characterize the biology of this rare disease; only with this crucial knowledge will men with breast cancer be properly treated in the future, which will definitely improve both their survival and quality of life.” Of all cancers diagnosed in males, breast cancer accounts for less than one percent, and male breast cancer also accounts for less than one percent of all breast cancer diagnoses. …

Orphan receptor proteins deliver two knock-out punches to glioblastoma cells — ScienceDaily

The scientists say when activated, one protein, called the short form, stops glioblastoma cells from replicating their DNA, and the other, called the long form, prevents cell division if the DNA has already been replicated, explains Rebecca Riggins, PhD, assistant professor of oncology at Georgetown Lombardi. The study was posted online Dec…

New study finds promising drug doubled positive effect in hormone-receptor positive breast cancer — ScienceDaily

An investigational drug discovered and being developed by Pfizer Inc., palbociclib targets a key family of proteins (CDK4/6) responsible for cell growth by preventing them from dividing. Results of the multi-year phase 2 study showed a significant increase in progression-free survival (PFS0 for patients with advanced breast cancer that was estrogen receptor positive (ER+), HER2-negative (HER2-), who were given a combination of the standard anti-estrogen treatment letrozole and palbociclib, compared to letrozole alone. …

Islet cell transplantation after pancreas removal may help preserve normal blood sugar

Chronic pancreatitis (CP) is an inflammatory disease that over time leads to loss of function of the pancreas and manifests with intractable pain, malabsorption and diabetes. While medical management and pain control are the initial approaches to CP, some patients need to undergo more invasive procedures to relieve ductal pressure in the pancreas. If those measures fail, surgical options can include total removal of the pancreas (total pancreatectomy, TP) or the Whipple procedure to remove part of the pancreas. Total pancreas removal produces diabetes because insulin-secreting cells are removed…

GPs should be more open when referring patients for cancer investigations, study says

They found that patients were rarely involved in the decision to be referred for investigation and that reasons for referral tended to be couched in non-specific terms rather than ‘cancer investigation’, even when the patient was on a cancer-specific pathway. The National Institute for Health and Care Excellence (NICE) referral guidelines emphasise that the patient should be involved in the decision-making process and be informed of the reasons for referral…

Promising drug doubled positive effect in hormone-receptor positive breast cancer, study finds

An investigational drug discovered and being developed by Pfizer Inc., palbociclib targets a key family of proteins (CDK4/6) responsible for cell growth by preventing them from dividing. Results of the multi-year phase 2 study showed a significant increase in PFS for patients with advanced breast cancer that was estrogen receptor positive (ER+), HER2-negative (HER2-), who were given a combination of the standard anti-estrogen treatment, letrozole, and palbociclib compared to letrozole alone. “We’re essentially putting the brakes on cell proliferation and causing these tumor cells to stop growing,” said Dr. …

Promising drug doubled positive effect in hormone-receptor positive breast cancer, study finds — ScienceDaily

An investigational drug discovered and being developed by Pfizer Inc., palbociclib targets a key family of proteins (CDK4/6) responsible for cell growth by preventing them from dividing. Results of the multi-year phase 2 study showed a significant increase in PFS for patients with advanced breast cancer that was estrogen receptor positive (ER+), HER2-negative (HER2-), who were given a combination of the standard anti-estrogen treatment, letrozole, and palbociclib compared to letrozole alone. …